Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT-7012 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced Solid Tumours
2025-523758-15-00Phase 2Authorised
- Sponsor
- Domain Therapeutics
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of DT-7012 in Nonhematologic neoplasms (2 arms), sponsored by Domain Therapeutics. Primary endpoint: Safety and tolerability of DT-7012 (monotherapy and in combination). Planned start Jan 2026; status: authorised.
02
Drugs
DT-7012
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-523758-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523758-15-00.